ALLMedicine™ Ameloblastoma Center

Feb 1st, 2023 - Alloplastic total temporomandibular joint replacement (TMJR) is the treatment of choice for end-stage temporomandibular joint diseases. Extended TMJR (eTMJR) is a modification of the standard alloplastic fossa-condyle joint that includes component...

Jan 31st, 2023 - Ameloblastoma (AM) is a rare epithelium-derived odontogenic tumor, mostly involving the mandible and less often the maxilla. Most AMs are benign and characterized by indolence and local invasiveness, with a high recurrence rate. Herein, we present...

Jan 31st, 2023 - Ameloblastomas are a group of common odontogenic tumors that originate from the dental epithelium. These tumors are aggressive in nature and present as slow growing painless cortical expansion of the jaw. Histologically, the follicular and plexifo...

Jan 17th, 2023 - Ameloblastoma may present a significant treatment challenge in the locally advanced, recurrent and metastatic setting. Comprehensive genomic profiling (CGP) can identify targetable genomic alterations to aid in treatment. Ameloblastoma samples wer...

Jan 12th, 2023 - The advances in molecular technologies have allowed a better understanding of the molecular basis of odontogenic cysts and tumours. PTCH1 mutations have been reported in a high proportion of odontogenic keratocyst. BRAF p.V600E are recurrent in am...

Nov 22nd, 2021 - Objectives: To investigate the outcomes of fenestration decompression combined with secondary curettage (FDSC) in the surgical treatment of jaw ameloblastoma. Methods: Medical records of patients diagnosed as multicystic ameloblastoma (MA) or unic...

Jan 21st, 2020 - PRIMARY OBJECTIVES: I. To observe the response rate of ameloblastoma to dabrafenib and trametinib at 6 weeks. SECONDARY OBJECTIVES: I. Feasibility and safety in this patient population. II. Response will be assessed pathologically. III. Two main h...

Jun 23rd, 2022 - The FDA has granted an accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors harboring a BRAF V600E mutation w...